TrialLancet (London, England)2025

Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

David Fiorentino et al.PubMed ↗Publisher ↗

No numbers read from the abstract.